Publications

Information provided in these publications, posters, and presentations is not considered medical advice and is not intended to promote the sale of any drug product.

May 27, 2020

23rd Annual MAD-ID Meeting

Real-world Utilization of Eravacycline in the Outpatient Setting

March 2, 2020

Open Forum Infectious Diseases

Early Experience with Eravacycline for Complicated Infections

February 21, 2020

Antimicrobial Agents and Chemotherapy

In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017

February 21, 2020

Antimicrobial Agents and Chemotherapy

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017

December 8, 2019

ASHP 2019

Real-World Use of Eravacycline: A Case Series

November 25, 2019

Open Forum Infectious Diseases

Carbapenem Treatment and Outcomes Among Patients With Culture-Positive Complicated Intra-abdominal Infections in US Hospitals: A Retrospective Cohort Study

October 29, 2019

Expert Review of Anti-infectant Therapy

Eravacycline for the treatment of complicated intra-abdominal infections

October 2, 2019

IDWeek 2019

In vitro Actvity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most commonly Isolated Ribotypes of Clostridioides difficile

October 2, 2019

IDWeek 2019

Activity of Eravacycline Against Contemporary Gram-negative Clinical Isolates from New York City Hospitals

October 2, 2019

IDWeek 2019

An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset “Low-Risk” Complicated Intra-Abdominal Infections Across US Hospitals

October 2, 2019

IDWeek 2019

Comparative evaluation of ETEST® ERV* bioMérieux with the CLSI broth microdilution method for eravacycline MIC determination

October 2, 2019

IDWeek 2019

In vitro activity and performance of available susceptibility testing methods for eravacycline against carbapenem-resistant Enterobacteriaceae

October 2, 2019

IDWeek 2019

Multicenter Evaluation of Eravacycline MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-negative MIC Panels

October 2, 2019

IDWeek 2019

Predictors of empiric carbapenem therapy in complicated intra-abdominal infections in the US, 2013-2017: a retrospective cohort study

October 2, 2019

IDWeek 2019

Novel Therapeutic Options for the Treatment of Multi-Drug Resistant Achromobacter Respiratory Infections

October 1, 2019

Clinical Therapeutics

Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration

October 1, 2019

Future Medicine

Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance

June 20, 2019

ASM Microbe 2019

Global In vitro Surveillance of Eravacycline Against Gram-negative and Gram-positive Clinical Isolates, Including Multidrug-Resistant Pathogens, Collected in 2017

June 20, 2019

ASM Microbe 2019

Activity of Eravacycline and Comparators Against 15,872 Bacterial Pathogens Isolated from Patients Receiving Care in Canadian Hospitals: CANWARD 2014-18

June 20, 2019

ASM Microbe 2019

Activity of cefiderocol (CFDC), ceftazidime-avibactam (CZA), and eravacycline (ERV) against carbapenem-resistant (CR) E. coli isolates from the US: Clonal Background, Resistance Genes, and Co-Resistance

June 20, 2019

ASM Microbe 2019

Comparative evaluation of Eravacycline MIC determination with the new ETEST® ERV* and CLSI broth microdilution method

May 24, 2019

Antimicrobial Agents and Chemotherapy

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

May 9, 2019

22nd Annual MAD-ID Meeting

Efficacy of Eravacycline in Obese Patients: Pooled Analysis of IGNITE1 and IGNITE4

May 9, 2019

22nd Annual MAD-ID Meeting

Eravacycline is Effective in High-Risk Complicated Intra-Abdominal Infection Subgroups

May 9, 2019

22nd Annual MAD-ID Meeting

Effect of Renal Function in IGNITE1 and IGNITE4: Two Phase 3 Studies to Evaluate the Efficacy and Safety of Eravacycline

May 9, 2019

22nd Annual MAD-ID Meeting

Microbiological Efficacy of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including MDR Isolates: A Pooled Analysis from IGNITE1 and IGNITE4, Two Phase 3 Trials of Complicated Intra-Abdominal Infection

May 9, 2019

22nd Annual MAD-ID Meeting

Multi-Site Evaluation of Eravacycline MIC Test Strip (MTS) Compared to Broth Microdilution MICs

April 13, 2019

ECCMID 2019

In Vitro Activity of Eravacycline and Comparators against Gram-positive Bacteria Collected from European Hospitals in 2017

April 13, 2019

ECCMID 2019

Multicenter Evaluation of Eravacycline in MIC Results for E. coli Using MicroScan Drief Gram Negative MIC Panels

April 13, 2019

ECCMID 2019

Surveillance of The In Vitro activity of Eravacycline and Comparators Against Clinical Isolates from Europe During 2017

April 13, 2019

ECCMID 2019

In vivo efficacy of TP-6076 in murine thigh and lung infection models challeneged with Acinetobacter baumannii

April 13, 2019

ECCMID 2019

Safety, Tolerability and Pharmacokinetics of Multiple Doses of TP-271, a Novel Fluorocycline, in Normal Healthy Subjects

April 3, 2019

AACR 2019

In Vitro Characterization of TP-2846: A Novel Tetracycline Antileukemia Agent

April 3, 2019

AACR 2019

Discovery and Structure-Activity Relationship of TP-2846: A Novel Tetracycline Antileukemia Agent

April 3, 2019

AACR 2019

In Vivo Activities of TP-2846: A Novel Tetracycline Antileukemia Agent

February 26, 2019

Antimicrobial Agents and Chemotherapy

Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects

February 20, 2019

Drugs

Eravacycline: A Review in Complicated Intra‑Abdominal Infections

December 18, 2018

Clinical Infectious Diagnosis

IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections

December 13, 2018

BMC Microbiology

Eravacycline activity against clinical S. aureus isolates from China: In vitro activity, MLST profiles and heteroresistance

October 24, 2018

Antimicrobial Agents and Chemotherapy

Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline

October 23, 2018

2018 ACCP Global Conference on Clinical Pharmacy

Efficacy of Eravacycline in Obese Patients: Pooled Anaysis of IGNITE1 and IGNITE4

October 23, 2018

2018 ACCP Global Conference on Clinical Pharmacy

Effect of Renal Function in IGNITE1 and IGNITE4: Two Phase 3 Studies to Evaluate the Efficacy and Safety of Eravacycline

October 6, 2018

IDWeek 2018

Pooled Analysis of Safety Data from Phase 2 and 3 Clinical Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections

October 6, 2018

IDWeek 2018

Safety, Tolerability and Pharmacokinetics of Multiple Doses of TP-6076, a Novel, Fully Synthetic Tetracycline, in a Phase 1 Study

October 6, 2018

IDWeek 2018

Presentation: TP-6076

October 6, 2018

IDWeek 2018

Efficacy of Eravacycline in Secondary Bacteremia: A Post Hoc Analysis of Two Phase 3 studies of Complicated Intra-Abdominal Infection

October 6, 2018

IDWeek 2018

Combined Microbiological Response Rates From Two Phase 3 Trials Demonstrating the Activity of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Pooled Analysis of IGNITE1 and IGNITE4

October 6, 2018

IDWeek 2018

Safety, Tolerability and Pharmacokinetics of Multiple Doses of TP-6076, a Novel, Fully Synthetic Tetracycline, in a Phase 1 Study

August 27, 2018

Antimicrobial Agents and Chemotherapy

Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline.

July 4, 2018

Anaerobe

In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species

June 29, 2018

Journal of Antimicrobial Chemotherapy

In Vitro Susceptibility of Beta-Lactamase-Producing Carbapenem-Resistant Enterobacteriaceae (CRE) to Eravacycline

June 25, 2018

Antimicrobicrobial Agents and Chemotherapy

Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits

June 7, 2018

ASM Microbe 2018

TP-6076 is active against bacterial isolates carrying emergent resistance types

June 7, 2018

ASM Microbe 2018

Eravacycline in vitro activity against clinical isolates obtained in the United States during 2016 from urinary and gastrointestinal sources, including drug resistant pathogens

June 7, 2018

ASM Microbe 2018

Microbiological Efficacy of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including MDR Isolates: A Pooled Analysis from IGNITE1 and IGNITE4, Two Phase 3 Trials of Complicated Intra-Abdominal Infection

June 7, 2018

ASM Microbe 2018

Global in vitro activity of eravacycline and comparators against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Staphylococcus aureus and Enterococcus spp. including multidrug-resistant (MDR) isolates from 2016

May 9, 2018

Making a Difference in Infectious Diseases 2018 Meeting

Results of IGNITE4: A Phase 3 Study to Evaluate the Efficacy and Safety of Eravacycline vs Meropenem in Complicated Intra-abdominal Infections

May 1, 2018

Diagnostic Microbiology and Infectious Disease

In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015

May 1, 2018

International Journal of Antimicrobial Agents

Assessment of In Vivo Efficacy of Eravacycline Against Enterobacteriaceae Exhibiting Various Resistance Mechanisms: A Dose-Ranging Study and PK/PD Analysis

May 1, 2018

Antimicrobial Agents and Chemotherapy

Evaluation of the In Vitro Activity of Eravacycline Against a Broad Spectrum of Recent Clinical Anaerobic Isolates

May 1, 2018

Antimicrobicrobial Agents and Chemotherapy

Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

April 22, 2018

38th Surgical Infection Society Annual Meeting

A post-hoc evaluation of the length of antibiotic therapy from IGNITE4: A phase 3 study of eravacycline and meropenem for complicated intra-abdominal infections

April 22, 2018

38th Surgical Infection Society Annual Meeting

Surveillance of the in vitro activity of eravacycline and comparators against clinical isolates from the USA from 2013-2016

April 21, 2018

28th European Congress of Clinical Microbiology and Infectious Diseases

Global Surveillance of In Vitro Activity of Eravacycline and Comparators Against Enterobacteriaceae, Stenotrophomonas maltophilia, Staphylococcus aureus, and Enterococcus spp Collected During 2016

April 21, 2018

28th European Congress of Clinical Microbiology and Infectious Diseases

Eravacycline In Vitro Activity Against European Clinical Isolates Obtained in 2016 From Urinary and Gastrointestinal Sources, Including Drug-Resistant Pathogens

April 21, 2018

28th European Congress of Clinical Microbiology and Infectious Diseases

Results of IGNITE4: A Phase 3 Study to Evaluate the Efficacy and Safety of Eravacycline vs Meropenem in Complicated Intra-abdominal Infections

April 21, 2018

28th European Congress of Clinical Microbiology and Infectious Diseases

Eravacycline Is Active Against Bacterial Isolates Carrying Emergent Resistance Types

March 17, 2018

International Journal of Antimicrobial Agent

Activity of TP-6076 Against Carbapenem-Resistant Acinetobacter baumannii Isolates Collected From Inpatients in Greek Hospitals

January 1, 2018

International Journal of Antimicrobial Agents

In Vitro Activity of the Novel Fluorocycline Eravacycline Against Carbapenem Nonsusceptible Acinetobacter baumannii

October 3, 2017

55th Infectious Diseases Society of America Annual Meeting

In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Recent Strains of Bacteroides species

October 3, 2017

55th Infectious Diseases Society of America Annual Meeting

Impact of Meal Timing on Eravacycline Exposure During the Oral Portion of an IV to Oral Transition Dosing Regimen

September 22, 2017

Antimicrobial Agents and Chemotherapy

The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques

August 1, 2017

Journal of Antimicrobial Chemotherapy

Antimicrobial Susceptibility of Clinical Isolates of Neisseria gonorrhoeae to Alternative Antimicrobials With Therapeutic Potential

July 25, 2017

Antimicrobial Agents and Chemotherapy

The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques

July 1, 2017

ASM Microbe

TP-6076, a Fully Synthetic Tetracycline Antibacterial Agent, Is Highly Potent Against a Broad Range of Pathogens, Including Carbapenem-Resistant Enterobacteriaceae

July 1, 2017

ASM Microbe

Safety, Tolerability, and Pharmacokinetics of Single Doses of TP-6076, a Novel Fully Synthetic Tetracycline, in a Phase 1 Study

July 1, 2017

Antimicrobial Agents and Chemotherapy

In Vivo Pharmacodynamic Target Assessment of Eravacycline Against Escherichia coli in a Murine Thigh Infection Model

June 1, 2017

ASM Microbe

Safety, Tolerability, and Pharmacokinetics of Single Intravenous Doses of TP-271, a Novel Fluorocycline Antibiotic

June 1, 2017

ASM Microbe

The Novel Fluorocycline TP-271 Is Efficacious in a Murine A baumannii Pneumonia Model

June 1, 2017

ASM Microbe

PK/PD of the Novel Fluorocycline Eravacycline in a Murine E coli Thigh Model

June 1, 2017

ASM Microbe

Pharmacokinetics of Eravacycline Following Intravenous Administration in Rabbits

June 1, 2017

ASM Microbe

Activity of Eravacycline Against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii

June 1, 2017

ASM Microbe

Pharmacokinetics-Pharmacodynamics of Efficacy for Eravacycline Against Escherichia coli in an In Vitro Infection Model

April 22, 2017

27th European Congress of Clinical Microbiology and Infectious Diseases

TP-6076 Is Active Against Carbapenem- and Polymyxin-Resistant Enterobacteriaceae and Acinetobacter baumannii

April 22, 2017

27th European Congress of Clinical Microbiology and Infectious Diseases

In Vitro Activity of the Novel Fluorocycline TP-6076 Against Carbapenem Nonsusceptible Acinetobacter baumannii

April 22, 2017

27th European Congress of Clinical Microbiology and Infectious Diseases

Comparative In Vitro Activity of Eravacycline, a Novel Fluorocycline, Against mcr-1-Positive Escherichia coli and Klebsiella pneumoniae

April 22, 2017

27th European Congress of Clinical Microbiology and Infectious Diseases

Eravacycline, a Novel Fluorocycline, Has Antibacterial Activity Against Carbapenem-Resistant Enterobacteriaceae (CRE) and Acinetobacter spp (CRA)

April 22, 2017

27th European Congress of Clinical Microbiology and Infectious Diseases

Antibacterial Activity of Eravacycline, a Novel Fluorocycline, Compared to Established Antimicrobials, Against Contemporary Clinical Isolates From Tanta, Egypt

April 22, 2017

27th European Congress of Clinical Microbiology and Infectious Diseases

In Vitro Activity of Eravacycline and Comparators Against Acinetobacter baumannii, Stenotrophomonas maltophilia, and Enterobacteriaceae, Including Carbapenem-Resistant and ESBL Phenotype Subgroups, Collected From European Hospitals in 2015

April 22, 2017

27th European Congress of Clinical Microbiology and Infectious Diseases

In Vitro Activity of Eravacycline and Comparators Against Staphylococcus aureus and Enterococci, Including Methicillin-Resistant and Vancomycin-Resistant Subgroups, Collected From European hospitals in 2015

April 9, 2017

26th European Congress of Clinical Microbiology and Infectious Diseases

TP-6076 Is Efficacious in a Mouse Pneumonia Model With Carbapenem-Resistant Acinetobacter baumannii (CRAB) and Retains Potency Against Common Tetracycline-Resistance Mechanisms

March 1, 2017

JAMA Surgery

Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE1) Trial: A Randomized Clinical Trial

February 22, 2017

mSphere

Fluorocycline TP-271 Is Potent Against Complicated Community-Acquired Bacterial Pneumonia Pathogens

December 21, 2016

Journal of Organic Chemistry

A Divergent Route to Eravacycline

October 26, 2016

54th Annual Meeting of the Infectious Diseases Society of America

In Vitro Global Surveillance of Eravacycline and Comparators Against Staphylococcus Spp and Enterococcus Spp Over a 3-Year Period (2013 to 2015)

October 26, 2016

54th Annual Meeting of the Infectious Diseases Society of America

In Vitro Global Surveillance of Eravacycline and Comparators Against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Including Multidrug-Resistant (MDR) Isolates, Over a 3-Year Period (2013 to 2015)

October 21, 2016

Antimicrobial Agents and Chemotherapy

Eravacycline Is Active Against Bacterial Isolates Expressing the Polymyxin Resistance Gene mcr-1

August 1, 2016

Antimicrobial Agents and Chemotherapy

Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo

August 1, 2016

Antimicrobial Agents and Chemotherapy

Antibacterial Efficacy of Eravacycline In Vivo Against Gram-Positive and Gram-Negative Organisms

June 16, 2016

ASM Microbe

In Vitro Activity of Eravacycline and Comparators Against Enterobacteriaceae, Including Strains Resistant to Carbapenems or Third and Fourth Generation Cephalosporins in the United States

June 16, 2016

ASM Microbe

In Vitro Activity of Eravacycline and Comparators Against Acinetobacter baumannii, Including Carbapenem-Resistant Strains, and Stenotrophomonas maltophilia Isolated from Patients in the United States

June 16, 2016

ASM Microbe

Eravacycline Is Active Against MDR, Cephalosporin- and Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii

June 16, 2016

ASM Microbe

Eravacycline In Vitro Activity Against Clinical Isolates Obtained From Genitourinary (GU) and Gastrointestinal (GI) Sources From Patients in the United States

June 16, 2016

ASM Microbe

Evaluation of Patients with Complicated Intra-abdominal Infections (cIAI) and Concomitant Bacteremia (CB) from IGNITE1: A Phase 3 Study to Evaluate the Efficacy and Safety of Eravacycline (ERV) vs Ertapenem (ETP) in Complicated Intra-abdominal Infections (cIAI)

June 16, 2016

ASM Microbe

Analysis of Baseline Pathogens and Clinical Efficacy in IGNITE1, a Phase 3 Study to Evaluate the Efficacy and Safety of Eravacycline (ERV) vs Ertapenem (ETP) in Complicated Intra-abdominal (cIAI) Infections

June 16, 2016

ASM Microbe

Risk Factors for Change in Outcome Between the End of Therapy (EOT) and Post-Treatment (PT) Evaluations in Patients With Complicated Urinary Tract Infections (cUTI) Treated With Eravacycline (ERV): Analysis From a Randomized, Double-Blind, Phase 3 Trial (IGNITE2)

June 16, 2016

ASM Microbe

Intravenous Eravacycline With Transition to Oral Therapy for Treatment of Complicated Urinary Tract Infections (cUTI) Including Pyelonephritis: Results From a Randomized, Double-Blind, Multicenter, Phase 3 Trial (IGNITE2)

June 16, 2016

ASM Microbe

Intravenous Eravacycline Compared to Intravenous Levofloxacin for the Treatment of Complicated Urinary Tract Infections (cUTI): Subgroup Analysis From a Randomized, Double-Blind, Phase 3 Trial (IGNITE2)

June 1, 2016

Antimicrobial Agents and Chemotherapy

In Vitro Activity of Eravacycline Against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii

May 18, 2016

36th Annual Meeting of Surgical Infection Society

A Pooled, Post Hoc Evaluation of the Length of Antibiotics Therapy From IGNITE1: A Phase 3 Study of Eravacycline (ERV) and Ertapenem (ETP) for Complicated Intra-abdominal Infections (cIAI)

April 9, 2016

26th European Congress of Clinical Microbiology and Infectious Diseases

In Vitro Activity of Eravacycline and Comparators in Gram-Negative Organisms, Including Drug-Resistant Phenotypes, Isolated From Respiratory Sources, in Europe

April 9, 2016

26th European Congress of Clinical Microbiology and Infectious Diseases

Eravacycline In Vitro Activity Against Clinical Isolates Obtained From Urinary and Gastrointestinal Sources, Including Drug-Resistant Pathogens, From Patients in Europe

April 9, 2016

26th European Congress of Clinical Microbiology and Infectious Diseases

In Vitro Activity of Eravacycline and Comparators Against Enterobacteriaceae, Including Subgroups of Strains With Resistance to Carbapenems or Third and Fourth Generation Cephalosporins, Isolated From Patients in Europe

April 9, 2016

26th European Congress of Clinical Microbiology and Infectious Diseases

In Vitro Activity of Eravacycline and Comparators Against Acinetobacter baumannii, Including Carbapenem-Resistant Strains, and Stenotrophomonas maltophilia Isolated From Patients in Europe

April 1, 2016

Drugs

Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent

December 14, 2015

Antimicrobial Agents and Chemotherapy

Activity of Eravacycline Against Escherichia coli Clinical Isolates from US Veterans (2011) in Relation to Coresistance Phenotype and Sequence Type 131 Genotype

October 18, 2015

20th North American International Society for the Study of Xenobiotics Meeting

An Open-Label, Single-Dose Study Designed to Assess the Metabolism and Mass Balance Recovery for [14C]-Eravacycline in Healthy Male Subjects After Oral and Intravenous Dosing

October 7, 2015

53rd Infectious Diseases Society of America Annual Meeting

Activity of Eravacycline Against North American and European Enterobacteriaceae, Including Multidrug-Resistant Isolates, Collected in 2013–2014

October 7, 2015

53rd Infectious Diseases Society of America Annual Meeting

Activity of Eravacycline Against Anaerobic Bacteria from Europe Collected in 2013-2014

September 17, 2015

55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Assessment of Eravacycline Against Recent Gastrointestinal (GI) and Genitourinary (GU) Clinical Isolates Collected During 2013-2014

September 17, 2015

55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Assessment of Eravacycline Against Nonfermenting Gram-Negative Clinical Isolates Isolated in 2013-2014

September 17, 2015

55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Assessment of Eravacycline Against 3467 Recent Gram-Positive Bacteria, Including Multidrug-Resistant Isolates Collected From 2013-2014

September 17, 2015

55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Assessment of Eravacycline Against a Recent Global Collection of 4462 Enterobacteriaceae Clinical Isolates (2013-2014)

September 17, 2015

55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Results in Higher Risk Subgroups from IGNITE1: A Phase 3 Study to Evaluate the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections

September 17, 2015

55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Effect of Renal Function on Efficacy in IGNITE1: A Phase 3 Study to Evaluate the Efficacy and Safety of Eravacycline

September 1, 2015

Antimicrobial Agents and Chemotherapy

Erratum for Grossman et al. Target- and Resistance-Based Mechanistic Studies With TP-434, a Novel Fluorocycline Antibiotic

April 25, 2015

25th European Congress of Clinical Microbiology and Infectious Diseases

Efficacy Evaluation of TP-271, a Novel Fluorocycline, in a Neutropenic Murine Pneumonia Model Against Susceptible and Resistant Gram-Positive Pathogens

April 25, 2015

25th European Congress of Clinical Microbiology and Infectious Diseases

TP-6076 Is Active In Vitro Against Biofilms Formed by a Panel Containing Fluoroquinolone-Resistant and Susceptible Uropathogenic Escherichia coli Clinical Isolates

April 25, 2015

ECCMID 2019

In vitro Activities of Novel Tetracyclines Against Molecularly Characterized Carbapenem-resistant Gram-negative Pathogens

March 1, 2015

Antimicrobial Agents and Chemotherapy

Activity of Eravacycline Against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, From New York City

February 17, 2015

Antimicrobial Agents and Chemotherapy

Eravacycline (TP-434) Is Efficacious in Animal Models of Infection

January 26, 2015

Antimicrobial Agents and Chemotherapy

Eravacycline (TP-434) Is Active In Vitro Against Biofilms Formed by Uropathogenic Escherichia coli

January 20, 2015

Antimicrobial Agents and Chemotherapy

In Vitro Susceptibility Testing of Eravacycline Is Unaffected by Medium Age and Nonstandard Assay Parameters

September 5, 2014

54th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Efficacy of the Novel Fluorocycline TP-271 in a Mouse Model of Neisseria gonorrhoeae Infection

September 5, 2014

54th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Pharmacodynamic Evaluation Of TP-271, a Novel Fluorocycline, in a Neutropenic Murine Lung Model Infected With Streptococcus pneumoniae

September 5, 2014

54th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Pharmacodynamics of the Fluorocycline TP-271 in a Neutropenic Murine Lung Infection Model With Methicillin-Resistant Staphylococcus aureus

September 5, 2014

54th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy

Eravacycline Is Potent Against Third-Generation Cephalosporin- and Carbapenem-Resistant Enterobacteriaceae, Carbapenem-Resistant Acinetobacter baumannii, and Has Isolate-Specific Bactericidal Activity

September 5, 2014

54th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy

Association Between Eravacycline Activity and Efflux Expression in Strains of Acinetobacter baumannii

May 17, 2014

ASM General Meeting

TP-271 Is a Novel Fluorocycline Active Against Susceptible and Multidrug-Resistant Neisseria gonorrhoeae

May 10, 2014

24th European Congress of Clinical Microbiology and Infectious Diseases

In Vivo Efficacy of Novel, Fully Synthetic Tetracyclines in a Murine Lung Infection Model Challenged With KPC-Producing Klebsiella pneumoniae

May 10, 2014

24th European Congress of Clinical Microbiology and Infectious Diseases

Multi-Locus Sequence Typing of Escherichia coli Isolates From a Phase 2 Complicated Intra-abdominal Trial for Eravacycline

May 10, 2014

24th European Congress of Clinical Microbiology and Infectious Diseases

Eravacycline Does Not Prolong Corrected QT Intervals in a Thorough QT Study Conducted in Healthy Subjects

May 10, 2014

24th European Congress of Clinical Microbiology and Infectious Diseases

Eravacycline Protects in a Bacillus anthracis-Infected New Zealand White Rabbit Treatment Model

April 21, 2014

28th European Congress of Clinical Microbiology and Infectious Diseases

In Vitro Activity of Eravacycline and Comparators Against Resistant Gram-Negative Isolates Collected in 2016 From Patients in Europe

April 1, 2014

Antimicrobial Agents and Chemotherapy

Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of 2 Dose Regimens of Eravacycline vs Ertapenem for Adult Community-Acquired Complicated Intra-abdominal Infections

January 27, 2014

Antimicrobial Agents and Chemotherapy

Phase I, Open-Label, Safety and Pharmacokinetic Study to Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women

January 27, 2014

12th Annual ASM Biodefense and Emerging Infections Meeting

Eravacycline Is Efficacious in a Francisella tularensis-Infected Cynomolgus Monkey Model

November 1, 2013

Antimicrobial Agents and Chemotherapy

Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, Against Hospital and Community Pathogens

September 18, 2013

Journal of Medicinal Chemistry

Synthesis and Biological Evaluation of 8-Aminomethyltetracycline Derivatives as Novel Antibacterial Agents

September 10, 2013

53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Pharmacokinetic/Pharmacodynamic (PK/PD) and Dose Selection Analyses for Eravacycline Using Phase 2 Data From Patients With Community-Acquired Complicated Intra-abdominal Infections (cIAI)

September 10, 2013

53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Comparative Analysis of Eravacycline (TP-434) by Broth Microdilution and Disk Diffusion

September 10, 2013

53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Plasma Protein Binding of Eravacycline in Mouse, Rat, Rabbit, Cynomolgus Monkey, African Green Monkey, and Human Using Microdialysis

May 12, 2013

The American Conference on Pharmacometrics Inaugural Meeting

Development of an Empirical Model to Explain Atypical Nonlinear Plasma Protein Binding of Eravacycline

April 27, 2013

23rd European Congress of Clinical Microbiology and Infectious Diseases

The Fluorocycline TP-271 Is Potent Against Major Complicated Community-Acquired Bacterial Pneumonia (CABP) Pathogens

April 27, 2013

23rd European Congress of Clinical Microbiology and Infectious Diseases

Characterization of Baseline Pathogens and Microbial Eradication in a Phase 2 Trial for Treatment of Complicated Intra-abdominal Infections Comparing Eravacycline (TP-434) to Ertapenem

April 27, 2013

23rd European Congress of Clinical Microbiology and Infectious Diseases

Time to Defervescence as an Early Marker of Clinical Response in Patients With Complicated Intra-abdominal Infections Treated With Eravacycline or Ertapenem

April 27, 2013

23rd European Congress of Clinical Microbiology and Infectious Diseases

The Fluorocycline TP-271 Is Potent Against Major Complicated Community-Acquired Bacterial Pneumonia (CABP) Pathogens

April 6, 2013

Organic Process Research and Development

Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development

February 25, 2013

11th Annual ASM Biodefense and Emerging Diseases

Eravacycline Is Potent Against Category A and B Pathogens

February 25, 2013

11th Annual ASM Biodefense and Emerging Diseases

Eravacycline Is Potent Against Category A and B Pathogens

September 9, 2012

52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

TP-271 Is a Potent, Broad-Spectrum Fluorocycline With Activity Against Community-Acquired Bacterial Respiratory and Biothreat Pathogens

September 9, 2012

52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

TP-271 Is a Potent, Broad-Spectrum Fluorocycline With Activity Against Community-Acquired Bacterial Respiratory and Biothreat Pathogens

July 1, 2012

Antimicrobial Agents and Chemotherapy

In Vitro Activity of TP-271 Against Mycobacterium abscessus, M fortuitum, and Nocardia Species

February 21, 2012

Antimicrobial Agents and Chemotherapy

Target- and Resistance-Based Mechanistic Studies With TP-434, a Novel Fluorocycline Antibiotic

December 11, 2011

Journal of Medicinal Chemistry

Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad-Spectrum Antibacterial Agent

December 9, 2011

Journal of Medicinal Chemistry

Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral Efficacy

October 20, 2011

49th Infectious Diseases Society of America Annual Meeting

Pharmacokinetics, Safety and Tolerability of a Novel Fluorocycline, TP-434, Following Multiple Dose Administration

September 17, 2011

51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

TP-434 Has Potential to Treat Complicated Urinary Tract Infections (cUTI)

September 17, 2011

51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

TP-434 Is Synergistic In Vitro With Amphotericin B, Fluconazole, and Caspofungin Against Candida spp

May 7, 2011

Infectious Diseases Society of America

Eravacycline Is Active Against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii Isolates in the FDA-CDC Antimicrobial Resistance Isolate Bank Panels

May 7, 2011

21st European Congress of Clinical Microbiology and Infectious Diseases

Broad-Spectrum Fluorocycline TP-434 Has Oral Bioavailability in Humans

September 12, 2010

50th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy

Target- and Resistance-Based Mechanistic Studies With Fluorocyclines TP-434 and TP-271

September 12, 2010

50th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy

In Vitro Activity of Fluorocyclines Against Legionella pneumophila

September 12, 2010

50th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy

TP-271, a Novel Oral Fluorocycline for Community-Acquired Respiratory and Biothreat Pathogens

September 12, 2010

50th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy

In Vitro Activity of Fluorocyclines Against Legionella pneumophila

September 12, 2010

50th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy

Fluorocyclines: A New Class of Broad-Spectrum Tetracyclines With Antibacterial Properties

September 12, 2010

50th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy

TP-434 Is Metabolically Stable and Has Low Potential for Drug-Drug Interactions

September 12, 2010

50th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy

TP-271, a Novel Oral Fluorocycline for Community-Acquired Respiratory and Biothreat Pathogens

September 12, 2010

50th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy

Target- and Resistance-Based Mechanistic Studies With Fluorocyclines TP-434 and TP-271

September 12, 2010

50th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy

TP-434 Is a Novel Broad-Spectrum Fluorocycline

September 12, 2010

50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

TP-434 Is Highly Efficacious in Animal Models of Infection

September 12, 2010

50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Pharmacokinetics of TP-434 in Mouse, Rat, Dog, Monkey, and Chimpanzee

September 12, 2010

50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Population Pharmacokinetic Modeling of TP-434, a Novel Fluorocycline, Following Single- and Multiple-Dose Administration

September 12, 2010

50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

In Vitro Activity of Fluorocycline TP-434 Against Panels of Recent Bacterial Clinical Isolates

September 12, 2010

50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Phase 1 Single- and Multiple-Ascending Dose Studies of a Broad-Spectrum Fluorocycline, TP-434

September 12, 2010

50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Efficacy of Fluorocycline TP-434 in the Neutropenic Thigh Infection Model Is Predicted by AUC/MIC

Share information about Tetraphase

Cancel

Thank you!
Your email has been sent.

Thank you for your request.

Someone will contact you shortly.